These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 33678555)
1. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Wang HY; Tseng SP; Lu PL J Microbiol Immunol Infect; 2022 Feb; 55(1):86-94. PubMed ID: 33678555 [TBL] [Abstract][Full Text] [Related]
3. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center. Kulengowski B; Burgess DS Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens. Xu C; Chen T; Zhang S; Zhou C; Liao W; Fang R; Chen L; Zhou T Diagn Microbiol Infect Dis; 2022 Jul; 103(3):115712. PubMed ID: 35613493 [TBL] [Abstract][Full Text] [Related]
5. Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Vagnone PS; Witwer M; Castanheira M; Johnson JR Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152073 [TBL] [Abstract][Full Text] [Related]
6. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205 [TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
8. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421 [TBL] [Abstract][Full Text] [Related]
10. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627 [TBL] [Abstract][Full Text] [Related]
12. Effect of Porins and bla Balabanian G; Rose M; Manning N; Landman D; Quale J Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016. Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A; Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054 [TBL] [Abstract][Full Text] [Related]
14. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Canver MC; Satlin MJ; Westblade LF; Kreiswirth BN; Chen L; Robertson A; Fauntleroy K; La Spina M; Callan K; Jenkins SG Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262761 [TBL] [Abstract][Full Text] [Related]
15. Kurihara D; Matsumoto S; Kishi N; Ishii Y; Mori M Microbiol Spectr; 2022 Apr; 10(2):e0223521. PubMed ID: 35416695 [TBL] [Abstract][Full Text] [Related]
16. Imipenem-Relebactam Susceptibility in Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877 [TBL] [Abstract][Full Text] [Related]
17. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512 [TBL] [Abstract][Full Text] [Related]
18. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013 [TBL] [Abstract][Full Text] [Related]
20. In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan. Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Lin YT; Wang SF; Tseng SP; Lu PL Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33322803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]